NanoTemper Technologies announced that it has acquired Envue Technologies, a Swedish company specializing in Nanofluidic Scattering Microscopy (NSM), and has also launched its new Dianthus α application. The combined developments enhance NanoTemper’s biophysical analysis portfolio and strengthen its position across early-stage biopharmaceutical research, particularly in nucleic acid and protein therapeutic discovery.
The acquisition brings NSM, a label-free, single-molecule analytical technology that allows researchers to observe individual molecules in their native state. This approach offers greater visibility into molecular behavior than traditional screening methods, which rely on averaged measurements that can obscure critical variations in behavior and performance. The integration of NSM is expected to enhance confidence and decision-making in early discovery workflows, supporting the acceleration of next-generation therapeutic development.
With the launch of Dianthus α, NanoTemper expands the capabilities of its existing Spectral Shift and TRIC technologies. The Dianthus α application introduces Optical Unfolding to assess protein stability and Slow Kinetics to measure long-lasting molecular interactions. These features support the characterization of covalent binders and compounds with slow dissociation rates, which are often challenging to evaluate using standard binding assays. The addition of these capabilities is intended to enable researchers to assess hard-to-drug targets and reduce uncertainty in discovery programs more accurately.
Envue Technologies originated from the Langhammer Group at Chalmers University of Technology in Gothenburg. Its NSM technology provides real-time visualization and characterization of biomolecules without the need for labels or chemical modification. The acquisition allows NanoTemper to offer more comprehensive solutions spanning discovery through development.
NanoTemper will continue to collaborate with industry and academic partners to help streamline the process from data collection to therapeutic candidate selection. The company emphasized that its goal remains to support researchers in making faster and more confident decisions as drug modalities evolve and grow more complex.
KEY QUOTES:
“Integrating Envue’s label-free, single-molecule NSM technology into NanoTemper’s product portfolio, alongside the Spectral Shift technology that powers Dianthus α, marks an exciting step forward for researchers to advance next-generation therapeutics. As drug modalities grow increasingly complex, scientists need analytical tools that deliver clarity at the earliest stages. NSM will allow researchers to visualize individual molecules in ways not possible before, thereby reducing uncertainty and accelerating novel pathways to new therapies.”
Stefan Duhr, Chief Executive Officer and Co-founder, NanoTemper Technologies
“From the start, our goal at Envue was to see NSM technology reach scientists worldwide. We are confident NanoTemper will achieve this as they continue to strengthen their leadership in advancing biophysical tools.”
Ellen Andreasson, Co-founder and Chief Executive Officer, Envue Technologies
